Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kodak Deal On Hold Until Allegations Cleared

DFC Loan Of $765m Was Expected To Establish Pharmaceuticals Unit

Executive Summary

A major $765m loan agreed by the US International Development Finance Corporation to allow Kodak to establish a pharmaceuticals unit has been put on hold until allegations of wrongdoing are resolved, as rumors swirl about insider trading.

You may also be interested in...



Pharma Industry Reputation: What Is At Stake With COVID-19?

The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.

Deal Watch: RedHill Finds New Partner For Movantik

Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.

Kodak Establishes Pharmaceutical Unit To Tackle Shortages

Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel